RAPPORT THERAPEUTICS INC. Share Price Today: Live Updates & Key Insights
RAPPORT THERAPEUTICS INC. share price today is $26.8, up -1.38%. The stock opened at $27.75 against the previous close of $27.46, with an intraday high of $27.81 and low of $27.04.
RAPPORT THERAPEUTICS INC. Share Price Chart
RAPPORT THERAPEUTICS INC.
RAPPORT THERAPEUTICS INC. Share Price Performance
RAPPORT THERAPEUTICS INC. Institutional Holdings
RAPPORT THERAPEUTICS INC. Market Status
RAPPORT THERAPEUTICS INC. Fundamentals
Market Cap 1290.66 M
PB Ratio 2.5581
PE Ratio 0.0
Enterprise Value 807.62 M
Total Assets 512.43 M
Volume 496466
RAPPORT THERAPEUTICS INC. Company Financials
About RAPPORT THERAPEUTICS INC. & investment objective
Company Information Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company's lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. It also develops nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and migraine; and a9a10 nAChR for the treatment of hearing/vestibular disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.
Organisation Biotechnology
Employees 84
Industry Biotechnology
CEO Mr. Abraham N. Ceesay M.B.A.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
RAPPORT THERAPEUTICS INC. FAQs
What is the share price of RAPPORT THERAPEUTICS INC. today?
The current share price of RAPPORT THERAPEUTICS INC. is $26.8.
Can I buy RAPPORT THERAPEUTICS INC. shares in India?
Yes, Indian investors can buy RAPPORT THERAPEUTICS INC. shares by opening an international trading and demat account with Motilal Oswal.
How to buy RAPPORT THERAPEUTICS INC. shares in India?
You can easily invest in RAPPORT THERAPEUTICS INC. shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy RAPPORT THERAPEUTICS INC. shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of RAPPORT THERAPEUTICS INC..
Can I buy fractional shares of RAPPORT THERAPEUTICS INC.?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of RAPPORT THERAPEUTICS INC.?
RAPPORT THERAPEUTICS INC. has a market cap of $1290.66 M.
In which sector does RAPPORT THERAPEUTICS INC. belong?
RAPPORT THERAPEUTICS INC. operates in the Biotechnology sector.
What documents are required to invest in RAPPORT THERAPEUTICS INC. stocks?
To invest, you typically need:
What is the PE and PB ratio of RAPPORT THERAPEUTICS INC.?
The PE ratio of RAPPORT THERAPEUTICS INC. is N/A and the PB ratio is 2.56.